ClinicalTrials.gg
WithdrawnNCT06650839Updated Jan 7, 2026

POC for the Treatment of Subjects With Moderate AS Using Valvosoft® Non-Invasive Ultrasound Therapy

An interventional study of NIUT in Moderate Aortic Valve Stenosis, sponsored by Cardiawave SA. Withdrawn at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Cardiawave SA · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
company decision not to start the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a proof of concept looking at the safety of treating subjects with moderate aortic stenosis using a Non-Invasive Ultrasound Therapy.

Read the detailed description

Valvosoft, Ultrasound guided Non-Invasive Ultrasound Therapy (NIUT) medical device, delivers focused and controlled, short ultrasound pulses (\<20μsec), directed trans-thoracically at a high acoustic intensity (measured in watts per square centimeter (W/cm2), to produce non-thermal mechanical tissue softening of the targeted calcified aortic valve.

Echocardiographic live imaging enables to follow valve movements in real-time and thus target the therapeutic ultrasound on the calcified valve with great precision. This is first in human or proof of concept study.

02

Conditions studied

  • Moderate Aortic Valve Stenosis

Keywords

  • aortic stenosis
  • moderate
  • aortic valve
  • balloon valvuloplasty
  • TAVR
  • SAVR
  • Ultrasound
  • FUS
  • PCUT
  • NIUT
03

In context

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Cardiawave SA is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aortic Valve Area (AVA) ≥1.0 cm2 ≤ 1.5 cm2 and either mean aortic Pressure Gradient (mPG) of >25 - \< 40 mmHg or maximum velocity (Vmax) ≥3 ≤4 m/sec in normal flow conditions; or
  2. Normal-flow, low-gradient aortic stenosis (AS) with preserved (mean aortic Pressure Gradient (mPG) \<40 mmHg, Aortic Valve Area (AVA) ≥0.8 ≤1.0 cm2, Left Ventricular Ejection Fraction (LVEF) ≥50%, Stroke Volume Index (SVi) >35 mL/m2);
  3. Age ≥18 years;

Exclusion criteria

Exclusion Criteria:

  1. mPG ≥40 mmHg; or
  2. Severe aortic valve stenosis or other severe valve diseases; or
  3. Subject with severe aortic regurgitation; or
  4. Subjects with implanted mechanical or bioprosthetic valve in aortic position, or mechanical valve in any other positions; or
  5. Heart failure with a 3 or 4; or
  6. Cardiogenic shock or other hemodynamic instability; or
  7. ≤50%; or
  8. History of heart transplant; or
  9. Subject with a significant kidney disease ( ≤30 mL/min/1.73 m2) or subject is on dialysis; or
  10. Subject with uncontrolled hypertension defined as systolic Blood Pressure (BP) ≥160 mmHg and/or a diastolic BP ≥100 mmHg (mean of 3 measurements for both assessments); or
  11. Cardiac imaging evidence of vegetation; or
  12. Current endocarditis; or 13 Subject has a documented history of cardiac amyloidosis; or

14. Acute Myocardial Infarction (MI) ≤1 month prior to enrolment; or 15. Stroke or (TIA) ≤1 month prior to enrollment; or 16. Balloon Aortic Valvuloplasty (BAV) ≤3 months prior to enrollment; or 17. Leukopenia (WBC \<4000 cell/μL), anemia ( \< 8 g/dL), thrombocytopenia ( count \<50.000 cell/μL), or history of coagulopathy or hypercoagulable state.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment MAS

    Subjects will be treated with Valvosoft, Ultrasound guided Non-Invasive Ultrasound Therapy (NIUT) medical device, to reduce the symptoms caused by moderate aortic stenosis

    Device: NIUT

Interventions

  • DeviceNIUT

    Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft

06

What researchers measure

Primary outcomes

  1. Rate of MACE

    Rate of MACE defined as a composite of all-cause mortality, MI, stroke, rehospitalization for heart failure at 30 days.

    Time frame: from baseline to 30 days FU

  2. Improvement in leaflet mobility

    Change in leaflet mobility measured by means of a change in AVA

    Time frame: at 6 months FU compared to baseline

Secondary outcomes

  1. Rate of MACE

    Rate of MACE

    Time frame: at 6 , 12 , 18 , 24 months

  2. Rate of all Serious Adverse Events

    Rate of all Serious Adverse Events

    Time frame: peri-procedural and at 30 days, 3 , 6 , 12 , 18 , 24 months

  3. Rate of Stroke

    Rate of stroke (disabling and non-disabling; ischemic and hemorrhagic

    Time frame: at 30 days, 3 , 6 , 12 , 18 , 24 months

  4. Change of AS

    Change of AS by means of AVA( assessed by an independent echocardiographic CoreLab

    Time frame: at 30 days, 3 , 6 , 12 , 18 , 24 months compared to Baseline;

  5. Change in Quality of Life by means of KCCQ

    Improvement of quality of life by means of ansas City Cardiomyopathy Questionnaire (KCCQ). KCCQ is a 23-item, self-administered questionnaire.

    Time frame: at 30 days, 3 , 6 , 12 , 18 , 24 months compared to Baseline;

  6. Change in Quality of Life by means of EQ-5D

    Improvement of quality of life by means of EQ-5D. The EQ-5D descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

    Time frame: at 30 days, 3 , 6 , 12 , 18 , 24 months compared to Baseline;

  7. Change in Exercise capacity

    Improvement in VO2-max measured during Echo Spiro-Ergometry (ESE)

    Time frame: at 30 days, 6 , 12 , 18 , 24 months compared to Baseline;

07

Study locations

1 site
  • University Clinical Centre Serbia
    Belgrade, 11000, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Oct 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 21, 2024
StartEst.
Oct 2025
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06650839
Lead sponsor
Cardiawave SA
Collaborators
Micro Cro, TWrite
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Oct 2025 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 7, 2026

Study contacts

Milos Velinovic, MD, PhD
principal investigator · University Clinical Centre Serbia
Danijela Trifunovic-Zamklar, MD, PhD
principal investigator · University Clinical Centre Serbia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion